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Abstract
Background: Transcriptional regulation of gene expression is essential for cellular differentiation and function, and
defects in the process are associated with cancer. The ENCODE project has mapped potential regulatory sites across
the complete genome in many cell types, and these regions have been shown to harbour many of the somatic
mutations that occur in cancer cells, suggesting that their effects may drive cancer initiation and development.
The ENCODE data suggests a very large number of regulatory sites, and methods are needed to identify those that
are most relevant and to connect them to the genes that they control.
Methods: Predictive models of gene expression were developed by integrating the ENCODE data for regulation,
including transcription factor binding and DNase1 hypersensitivity, with RNA-seq data for gene expression. A penalized
regression method was used to identify the most predictive potential regulatory sites for each transcript. Known cancer
somatic mutations from the COSMIC database were mapped to potential regulatory sites, and we examined
differences in the mapping frequencies associated with sites chosen in regulatory models and other (rejected)
sites. The effects of potential confounders, for example replication timing, were considered.
Results: Cancer somatic mutations preferentially occupy those regulatory regions chosen in our models as most
predictive of gene expression.
Conclusion: Our methods have identified a significantly reduced set of regulatory sites that are enriched in
cancer somatic mutations and are more predictive of gene expression. This has significance for the mechanistic
interpretation of cancer mutations, and the understanding of genetic regulation.
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Background
The majority of work on the somatic mutations that are
found in cancer cell genomes has focussed on the ana-
lysis of protein coding exons. These regions have clear
functional significance, and because they represent only
a very small fraction of the genome are more amenable
to systematic experimental investigation (e.g. in whole
exome sequencing studies). Analysis of these data, taking
account of the relationship between mutational frequen-
cies and variables such as replication timing and gene
expression, has allowed the identification of recurrently
mutated regions and protein coding genes that when
mutated are likely to be oncogenic drivers [1].
The role of aberrant genetic regulatory processes in
the initiation and progression of cancer, for example the
constituent activation of transcription factors driven by
chromosomal re-arrangements [2], has been appreciated
for many years. More recently, the discovery of point
mutations in the TERT gene promoter that occur in
large percentages of cases in some cancer types and are
strongly linked to gene expression changes [3, 4], along
with developments in whole genome sequencing, have
focussed the field on mutations that occur in potential
regulatory elements within the genome. It has been
shown that regulatory regions harbour significant num-
bers of the somatic mutations that have been observed
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in cancer cell genomes [5], and this work has also pro-
vided some evidence of positive selection for mutations in
these regions, suggesting that regulatory mutations may
be important in promoting survival and reproduction of
cancer cells in the host. Other related work has examined
recurrently mutated regulatory elements [6] and discov-
ered regions potentially regulating genes with known in-
volvement in cancer. Further, a method for the discovery
of mutations that are strongly linked to expression levels
of nearby genes in cancer samples has been developed [7].
However, given the complexity of genetic regulation in
eukaryotic cells, it is likely that current work reveals only
a fraction of the regulatory aberrations driving cancer, and
there is a clear need for new methods that will reveal dif-
ferent insights.
New technologies for DNA sequencing have revolutio-
nised our ability to map regulatory regions of the gen-
ome. For example, the ENCODE project [8] has mapped
gene expression, transcription factor binding to DNA
and other relevant variables such as DNaseI hypersensi-
tivity and chromatin modifications on a whole genome
scale in many laboratory cell lines, and more recent
studies have examined the regulation of cellular differen-
tiation [9, 10]. These studies and others have led to the
development of databases, for example RegulomeDB
[11], and these provide a rich source of information on
potential regulatory elements. However, genetic regula-
tion operates at multiple levels, and despite the volume
of data now available it remains an unmet challenge to
convert this data into more detailed mechanistic under-
standing of the regulation of individual genes. A large
number of candidate regulatory elements are identified
in the genome by these technologies, and the possibility
that genes are regulated by elements that are relatively
distant in the genome makes the process of assigning
regulatory elements to genes very difficult. Nevertheless,
these large data sets allow the development of correla-
tive models whereby candidate regulatory elements may
be identified, and used to develop regulatory networks
linking them to the genes they control [12]. Similar work
has used logistic regression [13], and Thurman and co-
workers [14] introduced models that link DNaseI hyper-
sensitivity data in promoter and distal sites to identify
regulatory regions. While these methods are clearly use-
ful, independent experimental knowledge of the links be-
tween genes and their regulatory regions is presently too
limited for effective method comparison and validation.
A useful alternative view of the utility of correlative
models of genetic regulation is to examine them in the
context of relevant independent biological data, such as
the somatic mutations observed in cancer genomes. Here
we introduce our own model of genetic regulation based
on ENCODE and examine the mapping of cancer muta-
tions from the COSMIC [15] database to the regulatory
regions it identifies. This integration of two large public
sources of biological information through modelling, has
the potential to improve our understanding both of gen-
etic regulation and cancer.
Results
Figure 1 illustrates the process of building a simple cor-
relative model of gene expression for a single transcript.
As described in the Methods, candidate regulatory re-
gions (CRRs) were identified as the union of all sites of
transcription factor binding and the top 25% of DNase1
hypersensitive sites in all the ENCODE cell types consid-
ered. Each transcript was considered to be potentially
regulated by any CRR within 100 kB [16] of the tran-
scription start site (TSS), in this case 72 CRRs. Although
genes can be regulated by enhancers up to 1 MB from
the TSS, the figure of 100kB was chosen to encompass
most regulatory elements, for example those of the leu-
kaemia related oncogene Lmo2 [17]. The aim of our
model was to predict the expression level of the gene in
each of the cell types, as measured by RNA-seq experi-
ments, from signal intensities in DNase1 hypersensitivity
data, which we use as a crude measure of activity (e.g.
transcription factor binding) at the CRR concerned.
Given the large number of CRRs relative to the num-
ber of cell types in which gene expression was measured,
we adopted a penalised regression approach (LASSO) to
identify a small set containing just those elements with
the strongest relationships to gene expression. Analysis
of the LASSO data indicated that the best supported
models were based on just two candidate regulatory
elements per transcript. We subsequently refer to these
elements as the ‘chosen’ CRRs, and the remaining ele-
ments as ‘rejected’ CRRs. In the case of the transcript in
Fig. 1 a convincing model was constructed, showing a
(Pearson) correlation of observed to predicted expres-
sion values of 0.97 (Fig. 1b). We further assessed the
statistical significance of this model using a random-
isation approach, resulting in a p value of 0.0016 (see
Statistical significance of models in Methods). Figure 1c
and d show the correlation of DNaseI signal intensities
and expression for the two CRRs chosen by the LASSO
method, and Fig. 1e shows a example rejected CRR. The
genomic location of the CRRs is shown in Fig. 1f.
We next investigated the possibility of a large-scale
model building exercise for all genes/transcripts, and
also in a restricted set of 533 cancer census genes from
COSMIC [18]. We focussed on transcripts from GEN-
CODE v7, and restricted the study to transcripts
expressed in at least 7 cell types, which were more suit-
able for our regression based modelling techniques.
Thus our study focused on genes expressed in a wider
range of cell types, and we call these ‘globally expressed’
genes. The relevant statistics of model building are
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shown in Table 1, and a list of all chosen CRRs along
with their target genes is included in Additional file 1:
Table S1. Models were successfully built for approxi-
mately 9000 genes (16000 transcripts), and 290 genes
(650 transcripts) from the cancer set. It should be noted
that the scale of this model building exercise leads, after
correction for multiple testing, to a significant false
discovery rate. While any individual model should be
considered carefully in this light, we treated the exercise
as a means to the identification of a single set of CRRs
covering a substantial proportion of the transcriptome
that lead to the best supported models of gene expres-
sion (the chosen set), and a complement set of rejected
CRRs with weaker relationships to gene expression. It
should be noted that some elements were chosen for
more than one transcript, and this is illustrated in Fig. 2,
which also highlights the transcription factors known to
bind in each CRR. As an illustration of the results for
more genes, in Additional file 2: Figures S1 and S2 we
include four examples (WNT5A, ID1, LIMS1 and
TEAD3) where predicted CRRs coincide with regulatory
elements that are already known [19].
The COSMIC database [15] is a high-quality compil-
ation of somatic mutations that have been observed in
cancer cells. Mutations were downloaded from this data-
base (a total of 2.3 million mutations) and mapped to
the CRRs, as illustrated in Fig. 2. Overall 8% of these
mutations mapped to CRRs identified with the transcript
set defined above, and 14% of transcripts mapped to at
least one mutated CRR. Table 2 gives statistics showing
how these mutations are partitioned between chosen
and rejected CRRs from the modelling exercise. This
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Fig. 1 Building an expression model for CNN3 (ENST00000370206.4). a shows the mean squared error against the log (λ) LASSO penalty
parameter with numbers above the graph indicating the number of predictive variables (non-zero coefficients) in the corresponding LASSO
model. Dotted lines show possible choices of λ at minimum mean-squared error (λmin) and more conservatively at that value plus 1 standard
error. This identifies models with 2 predictive variables as optimal. b shows the correlation between observed expression and predicted
expression from the model. c and d show the correlation of DNaseI signal intensities and expression for the two candidate regulatory elements (CRRs)
chosen by the LASSO method. e shows the correlation between DNaseI signal intensities and expression for an example rejected CRR. f shows the
genomic location of the two chosen CRRs and one example rejected CRR
Shar et al. Molecular Cancer  (2016) 15:76 Page 3 of 9
shows that a significantly higher proportion of chosen
CRRs are mutated at least once compared rejected
CRRs, and that chosen CRRs harbour around 1.5 times
more mutations than rejected CRRs. This applies equally
to all genes and to the cancer related subset. Within the
all genes set all comparisons are highly statistically sig-
nificant, while the smaller cancer genes set shows the
same trends but with reduced levels of statistical signifi-
cance. When limiting the analysis to CRRs only from
higher quality expression models (confident models with
r > 0.7 and highly confident models with r > 0.8) the ef-
fect size increases: mutations are enriched in chosen
CRRs by a factor of 1.45 (=1.35/0.93) in all models and
this rises to 1.81 in CRRs for highly confident models.
It is known that DNA mutation frequencies are het-
erogeneous [1] over the genome, and are related to vari-
ables such as replication timing and GC content.
Equally, in the context of this analysis, average mutation
frequencies within CRRs might be expected to be af-
fected by the length of the CRR and possibly the prox-
imity to a transcription start site (TSS). We took two
different approaches to investigate whether these effects
could have biased the statistical considerations above.
First we repeated the significance tests on the mean
NAB2 STAT6 LRP1CCG Non-CCGCCG
Egr1, Bhlhe40, Gata2, 
Egata2, Sin3a, Nr2f2, 
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Fig. 2 The chosen CRRs for NAB2 (ENST00000342556.5), STAT6 (ENST00000300134.2) and LRP1 (ENST00000243077.2). Black arrows link CRRs to the
transcripts for which they were chosen in expression models; note that one CRR was chosen for both STAT6 and NAB2. Details of the chosen
CRRs are given red boxes, including the bound transcription factors, sizes of the CRRs and mutations mapped from the COSMIC database. CRRs
are labelled as enhancers if they show positive correlation with expression and repressors if they show negative correlation. The chosen CRRs are
marked as red boxes if there is at least one reported mutation in them, and black otherwise
Table 1 Statistics of model building
All transcripts Cancer set transcripts
Number of models attempted 17963 transcripts from 9209 genes 731 transcripts (from 304 genes)
Number of models built 16134 (8670 genes) 654 (292 genes)
Average r,r2 0.710, 0.519 0.718, 0.530
Range r2 0.004–0.99 0.048–0.925
Total candidate elements 678020 (mean 42/transcript) 28844 (mean 44/transcript)
Chosen elements 25045 (2/transcript) 1140 (2/transcript)
Elements chosen for 1 transcript 20025 999
Elements chosen for >1 transcript 5020 141
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number of mutations per CRR, this time not using the
entire set of rejected CRRs but by randomly choosing a
set of equal size to the chosen set matched according to
the variable concerned (e.g. matching each chosen set
member with a rejected member falling in the same GC
content bin). In the case of all variables (replication tim-
ing, GC content, length of CRR and proximity to a TSS)
the effects reported above remained significant, albeit
with reduced levels of significance reflecting the reduc-
tion in size of the rejected set. Second, to model all these
potential effects simultaneously we built generalised
linear models for the counts of mutations in CRRs. We
found the counts to be over-dispersed with respect to a
Poisson distribution assumption, and modelled this
with an additional dispersion parameter (see Methods).
The effect size for an indicator variable showing
whether a CRR was chosen or rejected was 0.46+/−0.02
(p < 2 × 10−16,Wald test), revealing a highly significant
effect on the (log) expected mutation counts consistent
in size with observed differences in average mutation
counts from Table 2.
Finally, within the chosen set of CRRs we tested for
differences in the average number of mutations in differ-
ent types of CRR. Chosen CRRs may be positively or
negatively correlated with expression of the associated
gene, and hence tentatively identified with enhancing or
repressing mechanisms. Of our chosen CRRs 32%
showed negative correlations with expression, but there
was no significant difference in mutation rates between
these two types of CRR, whether considering all models
or just those from cancer associated genes. On the other
hand dividing CRRs into proximal or distal according to
distance from the associated transcription start site
(distal > 10 kB, proximal < 10 kB) showed a significant
tendency for proximal CRRs to be mutated to higher
levels, as shown in Table 3 and previously reported [6].
This effect seems to be more pronounced in elements
identified with cancer associated genes.
Discussion
The recent revolution in DNA sequencing speed has
allowed us to map multiple variables relevant to genetic
regulation at genome-scale and sequence the genomes
of many individual cancers. The work reported here is
relevant to two important problems that arise from this
data: the first is to move from a descriptive understand-
ing of potential regulatory regions to a mechanistic un-
derstanding of the regulation of individual genes, and
the second to understand which somatic mutations in
cancer cells drive the process of cancer progression and
to identify underlying mechanisms.
In respect of the problem of understanding genetic
regulation, the genome scale data sets we have presently
still represent relatively little data for each individual
gene or transcript. The complexity of regulation in
eukaryotic cells, involving the interactions of transcrip-
tion factors and chromatin modifiers as well as miRNAs
and lncRNAs, and the potential involvement of DNA re-
gions (enhancers) distal to the transcript, mean that our
present levels of mechanistic insight are limited. Based
on the large scale data we have, the best that is possible
is the building of simple correlative models, which aim
to identify just those regions of the genome that seem
most strongly influential on gene expression. As we have
already commented, even this is subject to a significant
false discovery rate when attempted at genome-scale.
Table 2 Mapping of somatic mutations from COSMIC to candidate regulatory regions (CRRs)
Title All Cancer census genes
Chosen CRRs Rejected CRRs Chosen CRRs Rejected CRRs
Total number of CRRs 25045 158560 1140 7429
CRRs mutated at least once 3535 (14.11%)1 16241 (10.24%)1 160 (14.03%)2 703 (9.46%)2
Mean mutations/CRR 1.353 0.933 1.514 0.974
Mean mutations/CRR (models with r > 0.7) 1.403 0.883 1.635 0.955
Mean mutations/CRR (models with r > 0.8) 1.503 0.833 1.55 0.92
1Proportion mutated in chosen set greater than in rejected set, p < 10−15 (Chi-squared and Fisher test)
2Proportion mutated in chosen set greater than in rejected set, p < 10−5 (Chi-squared and Fisher test)
3Mean mutations in chosen set greater than in rejected set, p < 10−23 (two sample t test), p < 10−8 (Wilcoxon test)
4Mean mutations in chosen set greater than in rejected set, p < 0.05 (two sample t test and Wilcoxon test)
5Mean mutations in chosen set greater than in rejected set, p < 0.05 (two sample t test), p = 0.06 (Wilcoxon test)
Table 3 Mapping of mutations to chosen CRRs proximal and distal to the transcription start site
Proximal (<10kB from TSS) Distal (>10kB from TSS)
Mean mutations/CRR (all models) 2.301 1.251
Mean mutations/CRR (cancer related transcripts) 3.402 0.992
1Mean greater in proximal set, p < 10−39 (t-test), p < 10−17 (Wilcoxon)
1Mean greater in proximal set, p < 10−6 (t-test), p < 0.05 (Wilcoxon)
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Nevertheless, changes to genetic regulation are an im-
portant feature of cancer, and the results reported here
show that a set of candidate regulatory regions derived
from simple correlative models preferentially harbour
cancer somatic mutations, suggesting that these regions
are of functional significance in genetic regulation.
Conclusions
It is now recognised that mutations affecting regulatory
regions are potentially as important in cancer progres-
sion as mutations in protein coding regions or those that
directly alter functional RNA molecules. Here we have
shown that somatic mutations that are found in cancer
cells occur preferentially in those potential regulatory re-
gions that are revealed by the ENCODE data to be more
likely to be directly involved in the regulation of gene
expression levels. This adds to the growing body of work
in this area strongly suggesting that cancer progression
involves positive selection for mutations with regulatory
effects. This work also shows that modelling based on
large data compendia like ENCODE can identify gen-
omic regions which are potentially more strongly linked
to gene expression, and propose links to the regulated
genes. This could lead to more effective definition and
prioritisation of mechanistic hypotheses for cancer
somatic mutations, which will be accessible to confirm-
ation or refutation with further detailed laboratory
investigations.
Methods
Data sets and identification of candidate cis regulatory
regions
Data sets were downloaded from ENCODE [8] for hu-
man genome version hg19 as shown in Table 4. Candi-
date Regulatory Regions (CRRs) were defined as all
transcription factor binding sites (TFBS) found in the
five cell types for which ChIP-seq data for transcription
factors was available, plus the highest scoring 25% of
DNaseI hypersensitive (DHS) sites for all 14 cell types,
filtered to include only those with the H3K27ac active
enhancer mark in at least one cell type. We used DHSs
generated by the uniform processing pipeline of the EN-
CODE Analysis Working Group (AWG) for this study
[8], and similarly TFBS were taken from the ENCODE
standard data processing pipeline [8].
The DHS and TFBS were merged if they overlapped
by at least 1 base pair using bedtools [20] and the result-
ing merged regions were considered as the full set of
candidate regulatory regions (CRRs) for further analysis.
DNaseI-seq signal intensities for each CRR in the 14 cell
types (Table 4) were computed from the uniformly proc-
essed and normalised signal tracks using bwtool [21].
RNA-seq (whole-cell polyA+) transcript quantifica-
tions were downloaded from the ENCODE DCC portal
of UCSC genome browser [22]. The expression for any
transcript whose coordinates are defined by GENCODE
(version 7) [23] is the average FPKM (Fragments Per
Kilobase of transcript per Million sequenced reads) [24]
of all the replicates, and they were filtered for IDR (Irre-
producible Discovery Rate) < = 0.1. Further, only tran-
scripts that were expressed (FPKM > =1) in at least 7 of
the cell types defined in Table 4 were considered for all
our analysis given below (such data is more suitable for
our regression based modelling scheme). Our method-
ology is illustrated graphically in Fig. 3.
Model
For applicability in the largest number of cell types, we
based our model on DHS data and assumed a simple
linear relationship between transcript expression (log
(FPKM) values) and (log (signal intensity)) from the
DNaseI data in each CRR.
y ¼ k0 þ
Xn
i¼1kixi
Here y is the expression value of the transcript, xi the
DNaseI signal intensity in the ith CRR for that transcript
and n is the number of CRRs within 100 kb of the tran-
scription start site.
Since n is typically greater than the number of cell
types for which data were available, model fitting
demanded a penalised approach to limit the number of
non-zero ki coefficients. We chose LASSO regression
implemented in the R glmnet package [25], which repre-
sents a least squares/maximum likelihood fit penalised
with a term λ∑i = 1
n |ki|. We investigated a number of







1 K562 100 √ √ √
2 Gm12878 73 √ √ √
3 Hepg2 57 √ √ √
4 Helas3 54 √ √ √
5 H1hesc 47 √ √ √
6 A549 √ √
7 Ag04450 √ √
8 Bj √ √
9 Hsmm √ √
10 Huvec √ √
11 Mcf7 √ √
12 Nhek √ √
13 Nhlf √ √
14 Sknshra √ √
aTotal number of transcription factor ChIP-seq datasets considered, note that
data sets of CTCF, CTCFL and RNA polymerase II were not used
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different ways of determining appropriate values for the
penalty scaling parameter λ, using a selection of example
genes, and eventually chose conservatively so that two
non-zero ki parameters were determined for each model.
As shown in Fig. 1, this is consistent with the glmnet
package recommendation for choosing λ, as either λmin
(minimum mean square error) or this value plus one
standard error. CRRs are subsequently referred to as
‘chosen CRRs’ if they appear with a non-zero coefficient
in a LASSO model for at least one transcript, and
rejected CRRs if they were considered in the analysis
for any model but never associated with a non-zero co-
efficient. In the supplementary material we have in-
cluded an input data file (Additional file 3) and R code
(Additional file 4) to illustrate how the method can be
implemented.
Statistical significance of models
The quality of the models was assessed through the
(Pearson) correlation of predicted and observed gene ex-
pression values, using a leave-one-out cross validation
scheme. To further assess statistical significance we gen-
erated models from randomly permuted data: we fixed
the DHS data and generated 50000 random permuta-
tions of the gene expression values per transcript, calcu-
lating the empirical probability of obtaining a model
from the random data showing a correlation at least as
high as that for the model from the real data (using the
same value of λ in each case). Since randomization is
computationally expensive, we considered 12 models: 4
transcripts where the real model showed high correl-
ation of predicted and actual expression (~0.9), 4 with
moderate correlations (~0.5) and 4 where LASSO failed
to find models. We found that the distribution of ran-
dom model correlations was remarkably similar in all
these cases and therefore used the distribution from
these combined randomizations to generate p values for
all models. When studying the generation of models for
multiple genes we chose to control the false positive rate
using the Benjamini-Hochberg method.
Mapping cancer mutations to regulatory regions
Somatic cancer mutations were derived from the COS-
MIC database [15] v76 (Catalogue of somatic mutations
in cancer). 2.3 million somatic mutations were retrieved
and mapped to the CRRs defined above. Duplicate/re-
current mutations were eliminated so only one mutation
was considered at each genomic location.
Statistical significance of differences in mutation counts
The statistical significances of differences in the counts
of somatic mutations observed in chosen and rejected
CRRs were tested in several ways. Differences in the
average number of mutations per CRR were tested with
two-sample t-tests, and also equivalent non-parametric
Wilcoxon tests to account for possible non-normality.
To account for other possible effects that might bias
these considerations we also repeated these tests after
first balancing the chosen and rejected sets to have the
same distribution of any potential confounding variable.
This was achieved by sampling the rejected set of CRRs
randomly to match the distribution of a variable in the
chosen set, which was enabled by the significantly larger
size of the rejected set. The variables considered were
replication timing, base pair composition, length of the
CRRs and distance of the CRR to the transcription start
site (TSS). Replication timing and GC content data was
downloaded from the UCSC website: the wavelet-
smoothed signal of replication timing [26] for 9 cell









































Fig. 3 Graphical summary of the methodology employed
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each case data was binned in 4 equal bins and the
process required a chosen CRR to be matched by a
rejected CRR from the same bin.
As an alternative test of statistical significance which
enabled us to model all potential effects on mutation
counts together, we built generalised linear models using
the glm function in R. Mutation counts were modelled
as a function of length of CRR, replication timing, GC
content, shortest distance to a TSS and an indicator
variable for chosen/rejected CRRs. A log link function
was used, first under the assumption of a Poisson distri-
bution for the counts and then in cases of over-
dispersion using the quasipoisson option in glm, which
fits a dispersion parameter which is otherwise fixed at
unity. The statistical significances of the effects of each
variable were assessed from the standard Wald test sta-
tistics produced by glm.
Cancer census genes
A set of 533 cancer consensus genes were retrieved from
the COSMIC database of which 292 entered our analysis
(the others did not meet our modelling criterion of ex-
pressing in at least 7 cell types). These were analysed as
a separate subset to investigate any possible specific ef-
fects for genes known to be directly involved in cancer.
Additional files
Additional file 1: Identified regulatory sites containing somatic
mutations. (XLSX 2006 kb)
Additional file 2: Examples of four genes, where predicted CRRs coincide
with the regulatory elements that are already known. (PPTX 63 kb)
Additional file 3: Example of input data fi le for the predictive model.
(TXT 14 kb)
Additional file 4: R code for LASSO model building. (R 1 kb)
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